Skip to main content

Table 2 Health-care resources used after diagnosis of CNS diagnosis

From: Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

Chemotherapy including targeted therapy

185/218 (84.8%)

Use of trastuzumab- or lapatinib- based therapies

Trastuzumab

Lapatinib

Both

All

  1st line (n = 175)

118 (67.4%)

26 (14.9%)

2 (1.1%)

146 (83.4%)

  2nd line (n = 127)

63 (49.6%)

34 (26.8%)

1 (0.8%)

98 (77.2%)

  3rd line (n = 81)

39 (48.1%)

15 (18.5%)

2 (2.5%)

56 (69.1%)

  4th line (n = 48)

23 (47.9%)

9 (18.8%)

2 (4.2%)

34 (70.9%)

  5th line and more (n = 27)

7 (25.9%)

6 (22.2%)

None

13 (48.1%)

Radiotherapy

200/218 (91.7%)

  Whole brain radiotherapy only

166/218 (77.3%)

  1 cycle radiotherapy

173/218 (86.8%)

  2 cycles radiotherapy (SRS boost or EBRT)

25/218 (12.5%)

  Second SRS

2/218 (1.0%)

  SRS only

21/218 (9.6%)

  Both (whole-brain radiotherapy and SRS)

13/218 (6.0%)

  Whole-brain radiotherapy 2D

96/193 (49.7%)

  Whole-brain radiotherapy 3D

97/193 (50.3%)

  Median fractions per patient

10 (1–28)

Neurosurgery

29/218 (13.3%)

Emergency unit visits

159/218 (73%)

  Mean length of stay

14.9 days (95% - CI 13.2-16.7)

  Median length of hospital stay (days, range)

9 days (range 1–221)

  Mean number of complications leading to hospitalisation

0.44 (95/218)

  1. Data are presented as number of patients (%). EBRT: external beam radiotherapy; SRS: stereotactic radiosurgery; 2D: two-dimensional; 3D: three dimensional.